Prevalence of new and repurposed drug resistance and associated genetic variants among rifampicin-resistant Mycobacterium tuberculosis in Shenzhen, China: a population-based study
In brief
Bedaquiline resistance affected 4.3% of Shenzhen's drug-resistant TB patients
Among 561 people with multidrug- or rifampicin-resistant TB, resistance ranged from 1.1% for delamanid and pretomanid to 4.3% for bedaquiline. Prior exposure to these drugs was strongly associated with resistance, but resistant strains also appeared in people without prior exposure, with genomic clusters suggesting transmission; genetic testing identified resistance reliably when present but missed some cases.
- Journal
- International journal of antimicrobial agents (Q1)
- Published
- 12 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Dan Li, Jiancong Zhang, Peng Xu, Wenjie Lai, Shan Chen, Shuhao Cai, et al.
- PMID
- 43020391
- DOI
- 10.1016/j.ijantimicag.2026.108067
Why clinicians should know about it
- Picked for Microbiology (medical) (top studies of the week, 15 November 2026): TB drug susceptibility testing, resistance mutations, sequencing, and transmission surveillance
Abstract
OBJECTIVES: To determine the proportion of resistance to five new and repurposed drugs (NRDs), identify risk factors for resistance, and characterize associated genetic mutations and transmission among people with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) in Shenzhen, China. METHODS: Clinical isolates were collected from all people with MDR/RR-TB admitted to Shenzhen Third People's Hospital between January 2022 and December 2024. The minimum inhibitory concentrations of five NRDs - bedaquiline (BDQ), clofazimine (CFZ), delamanid (DLM), pretomanid (PMD) and linezolid (LZD) - were determined using the broth microdilution method. Risk factors for NRD resistance were identified using Firth's penalized logistic regression. Whole-genome sequencing (WGS) was performed on 99 isolates, including all NRD-resistant strains and randomly selected susceptible strains, to analyze resistance-conferring mutations, phylogeny, and clustering. RESULTS: Among 561 people with MDR/RR-TB, resistance proportions were BDQ 4.3%, CFZ 3.6%, DLM 1.1%, PMD 1.1% and LZD 1.4%. Prior NRD exposure (aOR=4.96; 95% CI, 1.95-12.61; P=0.001) and male gender (aOR=3.64; 95% CI, 1.15-11.56; P=0.028) showed strong positive associations with NRD resistance. BDQ exposure posed a higher risk of both BDQ- and CFZ-resistance than CFZ exposure. Based on the WHO mutation catalogue, WGS predicted NRD resistance with 100% specificity, sensitivity ranged from 16.7% to 75.0%. Notably, 37.5%-66.7% of resistant cases had no prior NRD exposure, and clustered isolates indicated transmitted resistance. CONCLUSION: NRD resistance among MDR/RR-TB patients in Shenzhen remains low. Although prior drug exposure is the primary risk factor, there is also evidence of transmitted resistance. NRD surveillance is essential to guide treatment and control transmission.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.